Jiejun Du
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria
Papers in
- Epidemiology 18
- Pneumonia and Respiratory Infections 8
- Respiratory viral infections research 7
-
- SARS-CoV-2 and COVID-19 Research 6
- SARS-CoV-2 detection and testing 3
- Co-authors
- Amanda Paschke (15 shared papers)Nicholas A. Kartsonis (4 shared papers)Joan R. Butterton (10 shared papers)Michelle Brown (11 shared papers)Robert Tipping (8 shared papers)Keith S. Kaye (5 shared papers)Helen W. Boucher (5 shared papers)Katherine Young (7 shared papers)
- Journals
- Open Forum Infectious Diseases (8 papers)Clinical Infectious Diseases (4 papers)Infectious Diseases and Therapy (1 paper)Gastroenterology (1 paper)Infection (1 paper)
- Partner nations
- United StatesRussiaUnited Kingdom
In The Last Decade
Jiejun Du
21 papers receiving 738 citations
Jiejun Du's Hit Papers
Peers
Comparison fields: 5 of 75
- Applied Microbiology and Biotechnology 264
- Molecular Medicine 500
- Pharmacology 390
- Clinical Biochemistry 74
- Critical Care and Intensive Care Medicine 56
Countries citing papers authored by Jiejun Du
This map shows the geographic impact of Jiejun Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiejun Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiejun Du more than expected).
Fields of papers citing papers by Jiejun Du
This network shows the impact of papers produced by Jiejun Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiejun Du. The network helps show where Jiejun Du may publish in the future.
Co-authors
The 25 scholars most cited alongside Jiejun Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections Hit paper breakdown → | 2019 | 284 |
| 2 | 2020 | 143 | |
| 3 | 2017 | 126 | |
| 4 | 2021 | 68 | |
| 5 | 2023 | 23 | |
| 6 | 2020 | 19 | |
| 7 | 2020 | 19 | |
| 8 | 2024 | 11 | |
| 9 | 2023 | 10 | |
| 10 | 2023 | 9 | |
| 11 | 2021 | 9 | |
| 12 | 2023 | 6 | |
| 13 | 2017 | 4 | |
| 14 | 2020 | 3 | |
| 15 | 2017 | 3 | |
| 16 | 2018 | 3 | |
| 17 | 2025 | 2 | |
| 18 | 2023 | 2 | |
| 19 | 2020 | 2 | |
| 20 | 2025 | 1 |
About Jiejun Du
Jiejun Du is a scholar working on Epidemiology, Infectious Diseases, Pharmacology, Molecular Medicine and Applied Microbiology and Biotechnology, having authored 22 papers that have together received 748 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (8 papers), Pneumonia and Respiratory Infections (8 papers), Respiratory viral infections research (7 papers), Antibiotic Resistance in Bacteria (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers), Antibiotic Use and Resistance (4 papers), Nosocomial Infections in ICU (3 papers) and SARS-CoV-2 detection and testing (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (264 citations), Molecular Medicine (500 citations), Pharmacology (390 citations), Clinical Biochemistry (74 citations) and Critical Care and Intensive Care Medicine (56 citations). Jiejun Du has collaborated with scholars based in United States, Russia and United Kingdom. Frequent co-authors include Amanda Paschke, Nicholas A. Kartsonis, Joan R. Butterton, Michelle Brown, Robert Tipping, Keith S. Kaye, Helen W. Boucher, Katherine Young, Hee‐Koung Joeng and Angela Aggrey. Their work appears in journals such as Open Forum Infectious Diseases, Clinical Infectious Diseases, Infectious Diseases and Therapy, Gastroenterology and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.